Navigation Links
3-V Biosciences Completes $20 Million Series C Financing
Date:6/21/2013

MENLO PARK, Calif., June 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the financing will be used to advance 3-V's lead oncology candidate into a Phase 1 clinical trial and to conduct ongoing preclinical studies of multiple virology leads generated by the company's integrated drug discovery process. Existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates participated in the round.

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"I am very pleased by the recognition of our efforts and continued support from our existing investors," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences. "3-V takes an integrated approach to building its pipeline by applying our proprietary screening methodology combined with our expertise in medicinal chemistry, drug discovery and development to generate proprietary therapeutic candidates that target key pathways in oncology and infectious diseases. Our lead oncology candidate has demonstrated compelling anti-tumor activity in pre-IND studies and with the funds from our Series C, we look forward to advancing into the clinic later this year."

3-V's lead molecule is one of a series of novel fatty acid synthase (FASN) inhibitors initially being developed to treat solid tumor cancers. FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V has demonstrated potent activity against multiple tumor types, including lung, breast, prostate and colon cancers. In addition, 3-V has demonstrated potential synergy of its FASN-inhibitors with cytotoxic agents. 3-V plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the third quarter and initiate first-in-human studies by the end of 2013.

"The team at 3-V has done an impressive job of generating a pipeline of novel therapeutic product candidates with promising activity in diverse oncology and infectious disease indications," said David Mott, General Partner of New Enterprise Associates and Chairman of the Board of 3-V Biosciences. "We are pleased to support 3-V's continued efforts as they advance their lead program into clinical development."

3-V is leveraging its screening platform, drug discovery and drug development capabilities to identify antiviral candidates that exploit the dependence of the virus on the host cell by blocking host-virus interactions. The leads in the company's pipeline are characterized by their novel mechanism of action, broad-spectrum antiviral activity and high barrier to resistance. 3-V is currently evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV).

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information

Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
650-561-8600

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com


'/>"/>
SOURCE 3-V Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Arkansas that offers insurance and financial preparation services, is providing an update on ... Rescue organization. , Rock City Rescue is a locally recognized nonprofit that provides ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
Breaking Medicine News(10 mins):